James M. Rossetti

628 total citations
37 papers, 384 citations indexed

About

James M. Rossetti is a scholar working on Hematology, Genetics and Oncology. According to data from OpenAlex, James M. Rossetti has authored 37 papers receiving a total of 384 indexed citations (citations by other indexed papers that have themselves been cited), including 29 papers in Hematology, 15 papers in Genetics and 8 papers in Oncology. Recurrent topics in James M. Rossetti's work include Acute Myeloid Leukemia Research (24 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (10 papers) and Hematopoietic Stem Cell Transplantation (8 papers). James M. Rossetti is often cited by papers focused on Acute Myeloid Leukemia Research (24 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (10 papers) and Hematopoietic Stem Cell Transplantation (8 papers). James M. Rossetti collaborates with scholars based in United States, Australia and Italy. James M. Rossetti's co-authors include John Lister, Richard K. Shadduck, Haifaa Abdulhaq, Bushra Haq, Salman Fazal, Entezam Sahovic, Cyrus Khan, Folefac Atem, Mazen S. Zenati and Jeffrey Gryn and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

James M. Rossetti

34 papers receiving 375 citations

Peers

James M. Rossetti

HEMAT

GENET

ONCOL

PHEOH

Masaki Toshima Japan

R. M. Stone United States

Sophie Dimicoli United States

Margaret M. Showel United States

Esther Schuler Germany

Fengkuan Yu China

Rayaz Ahmed India

Wenyuan Mai China

Peter Noellke Germany

Ed Copelan United States

Masaki Toshima Japan

James M. Rossetti

143 ×0.6

HEMAT

155 ×0.8

64 ×0.5

GENET

54 ×1.3

ONCOL

27 ×0.8

PHEOH

Citations per year, relative to James M. Rossetti James M. Rossetti (= 1×) peers Masaki Toshima

Countries citing papers authored by James M. Rossetti

Since Specialization

Citations

This map shows the geographic impact of James M. Rossetti's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by James M. Rossetti with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites James M. Rossetti more than expected).

Fields of papers citing papers by James M. Rossetti

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by James M. Rossetti. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by James M. Rossetti. The network helps show where James M. Rossetti may publish in the future.

Co-authorship network of co-authors of James M. Rossetti

This figure shows the co-authorship network connecting the top 25 collaborators of James M. Rossetti. A scholar is included among the top collaborators of James M. Rossetti based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with James M. Rossetti. James M. Rossetti is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Hadid, Tarik, Ayad Al-Katib, José Binongo, et al.. (2023). Palifermin Compared to Supersaturated Calcium Phosphate Rinse in Prevention of Severe Oral Mucositis after Stem Cell Transplantation in Patients Receiving Radiotherapy-Based Myeloablative Conditioning. SHILAP Revista de lepidopterología. 4(1). 58–67. 1 indexed citations

Gill, Harinder, Francesca Palandri, David M. Ross, et al.. (2023). Bomedemstat (IMG-7289), an LSD1 Inhibitor, Manages the Signs and Symptoms of Essential Thrombocythemia (ET) While Reducing the Burden of Cells Homozygous for Driver Mutations. Blood. 142(Supplement 1). 747–747. 4 indexed citations

Rossetti, James M., et al.. (2023). An Analysis of Ruxolitinib Dosing for Myelofibrosis in Real-World Practice. Blood. 142(Supplement 1). 5186–5186. 1 indexed citations

Palandri, Francesca, Nicola Vianelli, David M. Ross, et al.. (2021). A Phase 2 Study of the LSD1 Inhibitor Img-7289 (bomedemstat) for the Treatment of Essential Thrombocythemia (ET). Blood. 138(Supplement 1). 386–386. 9 indexed citations

Agha, Mounzer, Anastasios Raptis, Jing‐Zhou Hou, et al.. (2021). A prospective study of the use of central venous catheters in patients newly diagnosed with acute myeloid leukemia treated with induction chemotherapy. Supportive Care in Cancer. 30(2). 1673–1679. 11 indexed citations

Schelbert, Erik B., et al.. (2019). Acute Myeloid Leukemia Presenting as Effusive Constrictive Pericarditis. CASE. 4(2). 97–102. 2 indexed citations

Agha, Mounzer, Anastasios Raptis, Jing‐Zhou Hou, et al.. (2018). Higher Number of Cycles of Cytarabine Consolidation Improves Outcomes in Elderly AML Patients. Blood. 132(Supplement 1). 4000–4000.

Lontos, Konstantinos, Mounzer Agha, Anastasios Raptis, et al.. (2017). Outcomes of patients diagnosed with acute myeloid leukemia after solid organ transplantation. Clinical Transplantation. 31(9). 1 indexed citations

Bilal, Mohammad, et al.. (2016). Paraneoplastic pemphigus as a presentation of acute myeloid leukemia. Hematology/Oncology and Stem Cell Therapy. 10(3). 155–160. 6 indexed citations

10.

Hilton, Christie, Cyrus Khan, James M. Rossetti, et al.. (2014). Efficacy and tolerability of treatment with azacitidine for 5 days in elderly patients with acute myeloid leukemia. Cancer Medicine. 3(6). 1570–1578. 15 indexed citations

11.

Garcia‐Manero, Guillermo, Emmanuel C. Besa, James M. Rossetti, et al.. (2013). Combination Therapy With Mocetinostat, An Oral, Spectrum-Selective Histone Deacetylase (HDAC) Inhibitor, and 5-Azaciditine: Indication Of Clinical Activity In MDS. Blood. 122(21). 1550–1550. 2 indexed citations

12.

Gilmore, Gary L., et al.. (2011). Viability and Potency of Hematopoietic Progenitor Cells after Prolonged Cryopreservation at –80°C. Acta Haematologica. 126(2). 99–102. 3 indexed citations

13.

Abdulhaq, Haifaa, Bushra Haq, Richard K. Shadduck, et al.. (2010). Activity of azacitidine in chronic myelomonocytic leukemia. Cancer. 117(12). 2690–2696. 88 indexed citations

14.

Lister, John, Jeffrey Gryn, Karina L. McQueen, et al.. (2007). Multiple Unit HLA-Unmatched Sex-Mismatched Umbilical Cord Blood Transplantation for Advanced Hematological Malignancy. Stem Cells and Development. 16(1). 177–186. 13 indexed citations

15.

Shadduck, Richard K., et al.. (2007). Recent advances in myelodysplastic syndromes. Experimental Hematology. 35(4). 137–143. 23 indexed citations

16.

Abdulhaq, Haifaa & James M. Rossetti. (2007). The role of azacitidine in the treatment of myelodysplastic syndromes. Expert Opinion on Investigational Drugs. 16(12). 1967–1975. 18 indexed citations

17.

Rossetti, James M., et al.. (2007). Response to azacitidine in patients with myelodysplastic syndrome with marrow fibrosis. Journal of Clinical Oncology. 25(18_suppl). 7089–7089. 1 indexed citations

18.

Rossetti, James M., Richard K. Shadduck, Robert Kaplan, et al.. (2006). Treatment of acute myelogenous leukemia with outpatient azacitidine. Cancer. 107(8). 1839–1843. 64 indexed citations

19.

Rossetti, James M., et al.. (2006). G-CSF Increases Hematological Response among Patients with Myelodysplasia Treated with Azacitidine.. Blood. 108(11). 4868–4868. 6 indexed citations

20.

Rossetti, James M., John Lister, RK Shadduck, et al.. (2003). Localized Lymphoid Relapse in the Pancreas Following Allogeneic Hematopoietic Stem Cell Transplant for Chronic Myelogenous Leukemia. Leukemia & lymphoma. 44(6). 1071–1074. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact